Novartis buys Pharming priority review voucher for a song

Pharming has agreed a deal to sell a recently awarded priority review voucher (PRV) to Novartis for around $21 million - well below the market rate.

Pharming brings first drug for rare disease APDS to US

Dutch biotech Pharming has claimed FDA approval for Joenja, the first drug indicated for recently identified rare immunodeficiency disorder activated phosphoinositide 3-ki

Pharming files rare disease drug leniolisib in Europe

Pharming has submitted its oral phosphoinositide 3-kinase delta (PI3Kδ) inhibitor leniolisib for approval in the EU as a treatment for activated PI3K delta syndrome (APDS), an ultra-rare di

CSL preps filings for once-monthly antibody for HAE

Australia's CSL has said its one-monthly treatment for hereditary angioedema has shown it is safe and effective in a phase 3 trial, and will be filed for approval in its current financial y

Pharming preps filing for rare disease drug leniolisib after...

Pharming has taken a step closer to getting a second product to market, after its rare disease therapy leniolisib met its objectives in a pivotal trial, setting up regulatory filings in the

CSL accuses ex-exec, now at Pharming, of stealing trade secr...